Phase 3 Study Comparing the Efficacy and Safety of Reloading Prasugrel and Clopidogrel in Acute Coronary Syndrome Patients With CYP2C19 Polymorphism Who Undergo Percutaneous Coronary Intervention.

Trial Profile

Phase 3 Study Comparing the Efficacy and Safety of Reloading Prasugrel and Clopidogrel in Acute Coronary Syndrome Patients With CYP2C19 Polymorphism Who Undergo Percutaneous Coronary Intervention.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Prasugrel (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Thrombosis
  • Focus Pharmacodynamics
  • Acronyms PRAISE-GENE
  • Most Recent Events

    • 28 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
    • 28 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top